Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: Multicenter phase II trial

Lung Cancer

Volumn 56, Issue 3, 2007, Pages 371-376

  Araya, Tomoyuki ^a   Kasahara, Kazuo ^a   Kimura, Hideharu ^a   Shibata, Kazuhiko ^b   Kita, Toshiyuki ^c   Shirasaki, Hiroki ^d   Hara, Johsuke ^a   Yoshimi, Yuzo ^e   Sone, Takashi ^a   Oribe, Yoshitaka ^a   Nobata, Kouichi ^f   Nishi, Kouichi ^f   Fujimura, Masaki ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b KOUSEIREN TAKAOKA HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^d FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^e Kaga Municipal Hospital Daishoji   (Japan)

^f ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Bi weekly schedule; Elderly patients; Gemcitabine; Non small cell lung caner; Phase II trial; Vinorelbine

Indexed keywords

GEMCITABINE; NAVELBINE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; RADIATION-SENSITIZING AGENTS; RETROSPECTIVE STUDIES; RIBONUCLEOTIDE REDUCTASES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 34247586533     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.01.001     Document Type: Article

References (18)

1. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan 2003. The Editorial Board of the Cancer Statistics in Japan, 2003.
2. Souquet P.J., Chauvin F., Boissel J.P., Cellerino R., Cormier Y., Ganz P.A., et al. Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 342 (1993) 19-21
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311 (1995) 899-909
4. Oshita F., Kurata T., Kasai T., Fukuda M., Yamamoto N., Ohe Y., et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86 (1995) 1198-1202
5. Maryska L.G.J.-H., Rob M.S., Peter P.A.R., and Mariad A. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 21 (1998) 105-113
6. Gridelli C. Chemotherapy of advanced non-small-cell lung cancer in the elderly: an update. Crit Rev Oncol Hematol 35 (2000) 219-225
7. Extermann M., Overcash J., Lyman G.H., Parr J., and Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582-1587
8. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
9. Frasci G., Lorusso V., Panzza N., Comella P., Nicollela G., Bianco A., et al. Gemcitabine plus vinorelbine yield better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 34 (2001) 65-69
10. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
11. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
12. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18 (2000) 2529-2536
13. Feliu J., Lopez Gomez L., Mandronal C., Espinosa E., Espinosa J., Giron C.G., et al. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients aged 70 years or older or patients who cannot receive cisplatin. Cancer 86 (1999) 1463-1469
14. Chen Y.M., Perng R.P., Chen M.C., Tsai C.M., Ming-Liu J., Whang-Peng J., et al. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 40 (2003) 221-226
15. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
16. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
17. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previous treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
18. Kimura H., Kasahara K., Shibata K., Sone T., Yoshimoto A., Kita T., et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naïve non-small cell lung cancer. J Thorac Oncol 1 (2006) 260-267